- Home
- GTEC vs CLRB Comparison
GTEC vs CLRB Comparison
Compare GTEC & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTEC
- CLRB
- Stock Information
- Founded
- GTEC 2006
- CLRB 2002
- Country
- GTEC United States
- CLRB United States
- Employees
- GTEC N/A
- CLRB N/A
- Industry
- GTEC Industrial Machinery/Components
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- GTEC Industrials
- CLRB Health Care
- Exchange
- GTEC Nasdaq
- CLRB Nasdaq
- Market Cap
- GTEC 21.2M
- CLRB 17.5M
- IPO Year
- GTEC N/A
- CLRB N/A
- Fundamental
- Price
- GTEC $1.21
- CLRB $4.50
- Analyst Decision
- GTEC
- CLRB Hold
- Analyst Count
- GTEC 0
- CLRB 2
- Target Price
- GTEC N/A
- CLRB N/A
- AVG Volume (30 Days)
- GTEC 159.8K
- CLRB 113.4K
- Earning Date
- GTEC 11-13-2025
- CLRB 11-17-2025
- Dividend Yield
- GTEC N/A
- CLRB N/A
- EPS Growth
- GTEC N/A
- CLRB N/A
- EPS
- GTEC 0.53
- CLRB N/A
- Revenue
- GTEC $81,601,160.00
- CLRB N/A
- Revenue This Year
- GTEC $3.28
- CLRB N/A
- Revenue Next Year
- GTEC N/A
- CLRB N/A
- P/E Ratio
- GTEC $2.32
- CLRB N/A
- Revenue Growth
- GTEC N/A
- CLRB N/A
- 52 Week Low
- GTEC $1.14
- CLRB $4.11
- 52 Week High
- GTEC $2.92
- CLRB $66.00
- Technical
- Relative Strength Index (RSI)
- GTEC 39.65
- CLRB 39.49
- Support Level
- GTEC $1.21
- CLRB $4.56
- Resistance Level
- GTEC $1.31
- CLRB $5.07
- Average True Range (ATR)
- GTEC 0.07
- CLRB 0.38
- MACD
- GTEC -0.01
- CLRB -0.11
- Stochastic Oscillator
- GTEC 13.64
- CLRB 2.42
About GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.